TABLE 1.
Description of study population demographics, N = 604
| Patients | N = 581 |
|---|---|
| Recipient sex (% of known) | |
| Female | 218 (38) |
| Male | 360 (62) |
| Missing (% of total) | 3 (1) |
| Ethnicity (% of known) | |
| African American | 84 (15) |
| Not African American | 489 (85) |
| Missing (% of total) | 8 (1) |
| Graft status (% of known) | |
| Tx failed after death | 3 (1) |
| Tx failed before death | 35 (7) |
| Tx functioning | 489 (93) |
| Missing (% of total) | 54 (9) |
| Biopsies | N = 604 |
| Indication for biopsy (% of known) | |
| For cause | 550 (92) |
| Surveillance | 47 (8) |
| Missing (% of total) | 7 (1) |
| Days from transplant to biopsy (median, range) | 580 (3–13 441) |
| Days from biopsy to follow-up (median, range) | 67 (1–621) |
| Days from biopsy to failure (median, range) | 29.5 (0–364) |
| DSA status (% of known) | |
| DSA negative | 243 (64) |
| DSA positive | 137 (36) |
| Missing (% of total) | 224 (37) |
| PRA status (% of known) | |
| PRA negative | 99 (37) |
| PRA positive | 171 (63) |
| Missing (% of total) | 334 (55) |
| C4d (% of known) | |
| Negative | 410 (77) |
| Positive | 121 (23) |
| Missing (% of total) | 73 (12) |
| MMDx diagnosis (% of total) | |
| AMR | 140 (23) |
| pAMR | 31 (5) |
| Mixed | 34 (6) |
| TCMR | 28 (5) |
| pTCMR | 9 (1) |
| cAKI | 50 (8) |
| Normal | 312 (52) |
| Histological rejection (% of known) | |
| AMR | 90 (17) |
| pAMR | 53 (10) |
| Mixed | 21 (4) |
| TCMR | 59 (11) |
| pTCMR | 45 (8) |
| cAKI | 29 (5) |
| BK | 20 (4) |
| No rejection | 228 (42) |
| Missing (% of total) | 59 (10) |
AMR, antibody-mediated rejection; BK, BK polyomavirus; cAKI, clinical acute kidney injury; DSA, donor-specific antibody; MMDx, Molecular Microscope Diagnostic System; pAMR, possible antibody-mediated rejection; PRA, panel reactive antibodies; pTCMR, possible TCMR; TCMR, T cell–mediated rejection.